SOURCE: IT & E International

December 19, 2006 11:10 ET

IT&E INTERNATIONAL and CORRELATE Announce Joint Marketing of K-Map FDA 21 CFR Part 11 Compliance Software Solution; Accelerates Life Sciences Products Time-to-Market

SAN DIEGO, CA and NEW YORK, NY -- (MARKET WIRE) -- December 19, 2006 -- IT&E International (, leading FDA compliance and validation consulting organization, and Correlate (, major provider of knowledge-based applications, announce a partnering agreement to provide K-Map FDA, Correlate's software solution for maximizing information assets.

Dr. George Van Lear, IT&E's President and Chief Validation Officer, explained, "IT&E International's life sciences experts working with K-Map FDA now have an extremely powerful tool to track, store and certify documents in the product research and development process as well as clinical trial phases. The end result will be decreased cycle times, accurate document tracking and approval, and increased productivity."

According to Halvor Kalve, Correlate's CEO, "21 CFR Part 11 companies need to look to effective methods for ensuring compliance with government policy and procedure while decreasing time-to-market and increasing competitiveness. K-Map FDA software solution applies Correlate's visual document management capability with leading collaborative and portal technologies. IT&E's extensive hands-on experience assisting pharmaceutical companies in validating compliance of 21 CFR Part 11 is a vital element in bringing products to market with rapid FDA approval."

K-Map FDA at-a-glance

Pre-defined templates specifically designed for compliance minimize costs, save time and streamline consulting. An added benefit of the software is reduction of human error by maintaining the integrity of the process, on and offline.

About IT&E International, Division of Averion International (OTCBB: AVRO)

IT&E international ( is a division of Averion International ( focusing on providing leading pharmaceutical companies with project-based consulting services in the areas of FDA Regulatory Compliance, data management, biometrics and clinical validation throughout the clinical trials lifecycle. The company, with its talented team of industry veterans with many years of biopharma experience, utilizes the latest tools and procedures to help its clients move quickly and effectively through the FDA approval process. Its services range from providing patients for drug trials, skilled personnel for trials, enterprise software and training to manage data and ensure FDA compliance and validation of new pharmaceutical manufacturing facilities to biostatistics support and analysis, audits, contract research services, data entry and verification services and providing total clinical solutions that take companies completely through Phase IV clinical trials. The company's pharmaceutical, biotech, healthcare and other life science client list includes such well-known companies as Abbott Laboratories, Amgen, Aventis Pasteur, Baxter Pharmaceutical, Bayer, Bristol-Myers Squibb, Chiron, Eli Lilly, Genentech, GlaxoSmithKline, Novartis, Pfizer, Purdue Pharmaceuticals, Schering-Plough, VaxGen, and Wyeth Global.

About Correlate AS

Correlate AS provides comprehensive and cost-effective solutions that enable enterprises to deploy knowledge-based applications, maximizing the investment in their information assets. Correlate K-Map solutions are used in almost all industry sectors -- from business intelligence at Yara International, case management at Freddie Mac, to energy management at Hydro. Correlate, founded in 1997, Correlate is headquartered in Holmestrand, Norway with additional offices in New York, San Jose, Indianapolis, and Buenos Aires. For more information visit our website:

Forward-looking Statement

Included in this release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct. The Company's actual results could differ materially from those anticipated in the forward-looking statements. The Company refers you to the cautionary statements and risk factors set forth in the documents it files with the Securities and Exchange Commission, including its most recent 10-KSB. The Company is under no obligation (and expressly disclaims any obligation) to update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact Information

  • For further information contact:
    Jim Murray
    IT&E International
    Email Contact
    Halvor Kalve
    Steven Swartz
    Email Contact